An update to rosacea treatment guidelines provides a comprehensive summary of management options, including expert evaluations–based on the phenotypes of each patient–to serve as a guide for tailoring treatment and care.
Mortality from systemic lupus erythematosus (SLE) is significantly higher among blacks.
Adverse childhood experiences (ACEs) are associated with worse patient-reported systemic lupus erythematosus (SLE) outcomes.
More than 60 percent of patients with lupus report that the disease has a large effect on their emotional and mental well-being.
The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
Investigators examine the association between various skin conditions and metabolic syndrome.
An observational study evaluated the effect of switching from one antimalarial agent to another agent in cutaneous lupus erythematosus after initial therapy was ineffective or not tolerated.
